 |
| Image Source: radiopaedia.org |
A recent article discussed the relationship between cancer and incidental pulmonary embolism (IPE). In the study, it was found that cancer patients who have this comorbid condition should ask their specialist for a long-term anticoagulant treatment. Analysts found that the risk of developing symptomatic recurrent venous thromboembolism (VTE) doubled among patients who did not receive an anticoagulant treatment.
Most importantly, the study confirmed the possible side effects of two common types of anticoagulation treatments. These are low-molecular-weight heparin (LMWH) and vitamin K antagonist. Data showed that patients who take vitamin K have a higher risk of major bleeding as compared to those undergoing LMWH.
 |
| Image Source: instituteofcancerpolicy.org |
IPE is said to occur in around 3 percent of all cancer patients, regardless of type or stage. Perhaps because of this low percentage or maybe because of the lack of studies analyzing the relationship between the two (as of the moment), treatment options designed for cancer-related IPE is limited. Medication and diagnosis is largely based on small observational studies.
Authors of the study agree that the results need to be further analyzed and tested. They note that there may be some ethical obstacles, but clarify that emphasis should be placed on cancer-related IPE. They resolve that unless greater importance is placed on this relationship, people of this condition will not receive the proper treatment. This may or may not delay their recovery period.
 |
| Image Source: nebraskamed.com |
As of now though, health professionals and pulmonary internists highly recommend the use of LMWH to treat cancer-related IPE. This treatment option significantly reduces the risk of developing VTE or any major bleeding.
Dr. Lisa Marie Cannon is a recognized internist, specializing in pulmonary medicine. Like this Facebook page for more medical news and updates.
